[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP0002426A2 - Oldékony interleukin-6-receptor/ligandum kiméraprotein és analógjai, valamint ezek alkalmazási eljárásai - Google Patents

Oldékony interleukin-6-receptor/ligandum kiméraprotein és analógjai, valamint ezek alkalmazási eljárásai

Info

Publication number
HUP0002426A2
HUP0002426A2 HU0002426A HUP0002426A HUP0002426A2 HU P0002426 A2 HUP0002426 A2 HU P0002426A2 HU 0002426 A HU0002426 A HU 0002426A HU P0002426 A HUP0002426 A HU P0002426A HU P0002426 A2 HUP0002426 A2 HU P0002426A2
Authority
HU
Hungary
Prior art keywords
sil
protein
chimeric
vector
naturally occurring
Prior art date
Application number
HU0002426A
Other languages
English (en)
Inventor
Judith Chebath
Orit Kollet
Tsvee Lapidot
Michel Revel
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0002426(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL12128497A external-priority patent/IL121284A0/xx
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of HUP0002426A2 publication Critical patent/HUP0002426A2/hu
Publication of HUP0002426A3 publication Critical patent/HUP0002426A3/hu
Publication of HU225855B1 publication Critical patent/HU225855B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgya az interleukin-6 (IL-6) biológiai aktivitásaivalfügg össze, melyek az oldható IL-6-receptor (sIL-6R) agonistaműködésével kapcsolatosak. Közelebbről, a találmány tárgyát olyan sIL-6R/IL-6-kiméraproteinek képezik, amelyek lényegében az sIL-6R és IL-6természetben előforduló alakja (illetve biológiailag aktív analógjaik)fuzionáltatásával vannak előállítva. Szintén a találmány tárgyátképezik a találmány szerinti kiméraproteineket kódoló DNS-szekvenciák,a találmány szerinti DNS-eket hordozó vektorok, a találmány szerintivektorokkal transzformált gazdasejtek, valamint eljárások a találmányszerinti kiméraproteinek előállítására és alkalmazására. A találmányszerinti kiméraproteinek (a rákos sejtek szaporodásának gátlása révén)különösen előnyösen alkalmazhatók rák kezelésére, továbbá csontvelő-átültetés hatékonyságának fokozására, májbetegségek kezelésére,valamint egyéb, IL-6-tal összefüggő állapotok kezelésére. Ó
HU0002426A 1997-07-10 1998-07-09 Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof HU225855B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12128497A IL121284A0 (en) 1997-07-10 1997-07-10 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL12281897A IL122818A0 (en) 1997-07-10 1997-12-30 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
PCT/IL1998/000321 WO1999002552A2 (en) 1997-07-10 1998-07-09 Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Publications (3)

Publication Number Publication Date
HUP0002426A2 true HUP0002426A2 (hu) 2000-11-28
HUP0002426A3 HUP0002426A3 (en) 2003-01-28
HU225855B1 HU225855B1 (en) 2007-11-28

Family

ID=26323470

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002426A HU225855B1 (en) 1997-07-10 1998-07-09 Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Country Status (27)

Country Link
US (2) US7198781B1 (hu)
EP (1) EP0991661B1 (hu)
JP (1) JP4402288B2 (hu)
KR (1) KR100505172B1 (hu)
CN (1) CN1185348C (hu)
AR (1) AR013201A1 (hu)
AT (1) ATE342915T1 (hu)
AU (1) AU758161B2 (hu)
BG (1) BG64680B1 (hu)
BR (1) BR9812096B1 (hu)
CA (1) CA2295936C (hu)
CY (1) CY1105895T1 (hu)
CZ (1) CZ302488B6 (hu)
DE (1) DE69836217T2 (hu)
DK (1) DK0991661T3 (hu)
EA (1) EA004793B1 (hu)
EE (1) EE05519B1 (hu)
ES (1) ES2271999T3 (hu)
HK (1) HK1031895A1 (hu)
HU (1) HU225855B1 (hu)
IL (2) IL122818A0 (hu)
NO (1) NO327397B1 (hu)
NZ (1) NZ502139A (hu)
PL (1) PL199212B1 (hu)
PT (1) PT991661E (hu)
SK (1) SK287039B6 (hu)
WO (1) WO1999002552A2 (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US5919763A (en) * 1998-06-01 1999-07-06 Hadasit Medical Research Services And Development Company Ltd. IL-6/SIL-6R complex for promotion of liver functions
US20040170604A1 (en) 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
DE69927375T2 (de) * 1998-07-06 2006-06-22 Tosoh Corp., Shinnanyo Fusionsprotein mit direkter verknüpfung des il-6-rezeptors mit il-6
AU777842B2 (en) * 1999-03-09 2004-11-04 Zymogenetics Inc. Novel cytokine Zalpha11 ligand
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
WO2001096565A2 (en) * 2000-06-16 2001-12-20 Asterion Limited Binding agents: chimeric ligand/receptor proteins
ATE324906T1 (de) * 2000-09-14 2006-06-15 Ares Trading Sa Verwendung von chimäres il6-il6r in huntingtonskrankheit
DE10106827A1 (de) * 2001-02-14 2002-09-05 Stefan Rose-John Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L)
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
IL147412A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
AU2003223089A1 (en) * 2002-04-29 2003-11-17 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
FR2850621B1 (fr) * 2003-02-04 2006-12-08 Journee Paul Connecteur reliant un bras d'essuie-glace a un balai d'essuyage, qui comporte deux languettes pour le verrouillage transversal de bras d'essuie-glace
DE10321317A1 (de) * 2003-05-13 2004-12-23 Christian-Albrechts-Universität Zu Kiel Verfahren zum Nachweis des funktionellen IL-6/ sIL-6-Rezeptor-Komplexes und Test-Kit zur Durchführung dieses Verfahrens
IL157309A0 (en) * 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
IL159558A0 (en) * 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2012261726B2 (en) * 2005-08-29 2015-03-12 Technion Research & Development Foundation Ltd. Media for Culturing Stem Cells
EP1962719A4 (en) 2005-08-29 2011-05-04 Technion Res And Dev Of Foundation Ltd MEDIA FOR BREEDING STEM CELLS
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
JP2009543579A (ja) * 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
EP3441459B1 (en) * 2006-08-02 2021-03-17 Technion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
GB0715216D0 (en) * 2007-08-03 2007-09-12 Asterion Ltd Leptin
CN101827857A (zh) * 2007-08-03 2010-09-08 埃斯特瑞恩有限公司 粒细胞集落刺激因子
WO2010003118A1 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
JP2012531885A (ja) * 2008-07-02 2012-12-13 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｉｌ６免疫治療剤
EP2387415A1 (en) 2009-01-16 2011-11-23 AGIRx Limited Vaccine compositions
EP3633025B1 (en) 2009-11-12 2022-09-14 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
ES2746482T3 (es) 2010-09-07 2020-03-06 Technion Res & Dev Foundation Nuevos métodos y medios de cultivo para cultivar células madre pluripotentes
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
CA2909576C (en) 2013-04-19 2023-07-18 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
EP3033415A4 (en) * 2013-08-12 2017-01-11 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of interest and il6
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN104826093A (zh) * 2015-04-16 2015-08-12 刘永庆 用于治疗慢性传染性肝病的Th2免疫反应拮抗剂及卵黄抗体
CN104922659B (zh) * 2015-07-03 2018-04-20 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
US20240269236A1 (en) 2021-06-04 2024-08-15 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
IL99803A (en) 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
PL190445B1 (pl) 1995-05-15 2005-12-30 Akademia Medyczna Im K Marcink Genetyczna szczepionka przeciwrakowa
DE19608813C2 (de) 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
KR100593981B1 (ko) * 1997-12-19 2006-06-30 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Ｉｆｎａｒ2/ｉｆｎ 복합체

Also Published As

Publication number Publication date
EE200000012A (et) 2000-08-15
EP0991661A2 (en) 2000-04-12
EA200000109A1 (ru) 2000-08-28
IL122818A0 (en) 1998-08-16
DE69836217D1 (de) 2006-11-30
JP4402288B2 (ja) 2010-01-20
EA004793B1 (ru) 2004-08-26
CA2295936A1 (en) 1999-01-21
SK62000A3 (en) 2000-07-11
US7198781B1 (en) 2007-04-03
HK1031895A1 (en) 2001-06-29
NO327397B1 (no) 2009-06-22
CN1185348C (zh) 2005-01-19
BG64680B1 (bg) 2005-11-30
NO20000086L (no) 2000-03-08
US20070172455A1 (en) 2007-07-26
EE05519B1 (et) 2012-02-15
JP2001509371A (ja) 2001-07-24
PL199212B1 (pl) 2008-08-29
NO20000086D0 (no) 2000-01-07
NZ502139A (en) 2002-03-28
PT991661E (pt) 2007-01-31
EP0991661B1 (en) 2006-10-18
PL338002A1 (en) 2000-09-25
AU8127198A (en) 1999-02-08
AR013201A1 (es) 2000-12-13
AU758161B2 (en) 2003-03-20
CZ200075A3 (cs) 2000-08-16
BR9812096A (pt) 2000-07-18
DE69836217T2 (de) 2007-08-23
KR20010021522A (ko) 2001-03-15
WO1999002552A2 (en) 1999-01-21
BR9812096B1 (pt) 2011-09-06
CN1269835A (zh) 2000-10-11
CY1105895T1 (el) 2011-02-02
CA2295936C (en) 2009-05-26
WO1999002552A3 (en) 1999-04-01
HUP0002426A3 (en) 2003-01-28
KR100505172B1 (ko) 2005-08-03
HU225855B1 (en) 2007-11-28
IL133972A (en) 2015-07-30
ATE342915T1 (de) 2006-11-15
DK0991661T3 (da) 2007-02-05
US7374912B2 (en) 2008-05-20
ES2271999T3 (es) 2007-04-16
CZ302488B6 (cs) 2011-06-15
BG104070A (en) 2000-11-30
SK287039B6 (sk) 2009-10-07

Similar Documents

Publication Publication Date Title
HUP0002426A2 (hu) Oldékony interleukin-6-receptor/ligandum kiméraprotein és analógjai, valamint ezek alkalmazási eljárásai
HUP0000317A3 (en) Process for the preparation of recombinant proteins in e.coli by high cell density fermentation
HUT61591A (en) Process for producing haemoglobin and its analogs
IE820069L (en) Recombinant dna encoding a polypeptide
IL88472A0 (en) Mammalian interleukin-1 receptor protein dnas and expression vectors encoding them,processes for producing them and pharmaceutical compositions containing them
EP0790255A3 (en) Cytotoxic lymphocyte maturation factor and monoclonal antibodies directed thereto
AU9084601A (en) G-csf analog compositions and methods
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
DE68929402D1 (de) Verfahren zur herstellung von wasserlöslichen polypeptiden
WO2004098530A3 (en) Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
CA2001303A1 (en) Endothelin dna and use thereof
IL88151A (en) Interleukin-7 protein, dna sequences encoding it, its preparation and compositions containing it
WO2000034474A3 (en) Growth factor homolog zvegf3
ES8504938A1 (es) Un metodo de producir una proteina interferon inmune humano
CA2011833A1 (en) Novel polypeptide and production thereof
AU2308992A (en) Cysteine depleted il-6 muteins
WO1992001782A3 (fr) Sucrose phosphate synthetase (sps), son procede de preparation, son adn complementaire et l'utilisation de l'adn complementaire pour modifier l'expression de la sps dans les cellules vegetales
CA2011378A1 (en) Achromobacter protease i gene and gene product thereof
NZ296562A (en) Recombinant peptides and secretory mehods for their preparation
CA2080008A1 (en) Water-soluble mutein of fibroblast growth factor (fgf) receptor
CA2051010A1 (en) Human luteinizing hormone-chorionic gonadotropin receptor protein, dna and use thereof
WO2002016584A3 (en) Process for the preparation of neutrophil inhibitory factor
AU637589B2 (en) Ancrod proteins, their production and use
CA2089111A1 (en) Smooth muscle mitogen and isolated dna coding therefor
CA2282734A1 (en) Aminopeptidase derived from bacillus licheniformis and process for preparation of natural type proteins

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees